BioLineRx Ltd. — Proxy Solicitation & Information Statement 2022

May 27, 2022

6-K 1 zk2227915.htm 6-K Licensed to: Z-K Global Document created using EDGARfilings PROfile 8.2.0.0 Copyright 1995 - 2022 Broadridge

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 OF

THE SECURITIES EXCHANGE ACT OF 1934

For the month of May 2022

Commission file number: 001-35223

---

BioLineRx Ltd.

(Translation of registrant’s name into English)

---

2 HaMa’ayan Street Modi’in 7177871, Israel

(Address of Principal Executive Offices)

---

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(1):_____

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(7):_____

The Registrant announces that it will hold an Annual Meeting of Shareholders on July 3, 2022, at 3:00 p.m. (Israel time) at the Registrant’s office, 2 HaMa’ayan Street, Modi’in, Israel. Attached hereto as Exhibit 1 , Exhibit 2 and Exhibit 3 , are, respectively, the Notice of Annual General Meeting and Proxy Statement, Proxy Card and Voting Instruction Card for holders of American Depositary Shares.

This Form 6-K, including all exhibits hereto, is hereby incorporated by reference into all effective registration statements filed by the registrant under the Securities Act of 1933.

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

BioLineRx Ltd.
By:	/s/ Philip A. Serlin
	Philip A. Serlin
	Chief Executive Officer

Dated: May 27, 2022